1
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Cetuximab Might Be Detrimental to Metastatic Colorectal Cancer Patients with KRAS Codon 12 Mutations.

      Read this article at

      ScienceOpenPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Anti-epidermal growth factor receptor (EGFR) monoclonal antibodies benefit patients with wild-type KRAS exon 2 metastatic colorectal cancer (mCRC). However, their effect in KRAS-mutant mCRC remains unclear.

          Related collections

          Author and article information

          Journal
          Anticancer Res.
          Anticancer research
          1791-7530
          0250-7005
          Jul 2015
          : 35
          : 7
          Affiliations
          [1 ] Department of Oncology, National Taiwan University, Hsin-Chu Branch, Hsinchu, Taiwan, R.O.C. Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan, R.O.C.
          [2 ] Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan, R.O.C. Graduate Institute of Clinical Medicine, College of Medicine, National Taiwan University, Taipei, Taiwan, R.O.C.
          [3 ] Department of Pathology, National Taiwan University Hospital, Taipei, Taiwan, R.O.C.
          [4 ] Division of Colorectal Surgery, National Taiwan University Hospital, Taipei, Taiwan, R.O.C. Department of Surgery, National Taiwan University Hospital, Taipei, Taiwan, R.O.C.
          [5 ] Department of Medical Research, National Taiwan University Hospital, Taipei, Taiwan, R.O.C.
          [6 ] Department of Medical Genetics, National Taiwan University Hospital, Taipei, Taiwan, R.O.C.
          [7 ] Department of Laboratory Medicine, National Taiwan University Hospital, Taipei, Taiwan, R.O.C. Department of Clinical Laboratory Sciences and Medical Biotechnology, College of Medicine, National Taiwan University, Taipei, Taiwan, R.O.C.
          [8 ] Department of Pathology, National Taiwan University Hospital, Taipei, Taiwan, R.O.C. Graduate Institute of Pathology, College of Medicine, National Taiwan University, Taipei, Taiwan, R.O.C.
          [9 ] Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan, R.O.C. Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan, R.O.C. Graduate Institute of Oncology, College of Medicine, National Taiwan University, Taipei, Taiwan, R.O.C.
          [10 ] Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan, R.O.C. Graduate Institute of Oncology, College of Medicine, National Taiwan University, Taipei, Taiwan, R.O.C. Graduate Institute of Clinical Medicine, College of Medicine, National Taiwan University, Taipei, Taiwan, R.O.C. khyeh@ntu.edu.tw.
          Article
          35/7/4207
          26124380
          c3ef4cf6-a75a-470f-a3d3-baf53266ed55
          History

          KRAS,epidermal growth factor receptor,metastatic colorectal cancer,Cetuximab

          Comments

          Comment on this article